4D Molecular Therapeutics Inc
$ 9.68
7.32%
23 Feb - close price
- Market Cap 553,068,000 USD
- Current Price $ 9.68
- High / Low $ 9.76 / 8.95
- Stock P/E N/A
- Book Value 7.89
- EPS -3.75
- Next Earning Report 2026-02-27
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.28 %
- ROE -0.45 %
- 52 Week High 12.34
- 52 Week Low 2.23
About
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops candidate products using its adeno-associated virus vectors. The company is headquartered in Emeryville, California.
Analyst Target Price
$33.11
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-10 | 2025-08-11 | 2025-05-07 | 2025-02-26 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-02-29 | 2023-11-09 | 2023-08-09 | 2023-05-10 | 2023-03-15 |
| Reported EPS | -1.01 | -0.98 | -0.86 | -0.9 | -0.79 | -0.63 | -0.66 | -0.75 | -0.24 | -0.77 | -0.88 | -0.84 |
| Estimated EPS | -1.01 | -0.73 | -0.8621 | -0.8379 | -0.7 | -0.7 | -0.74 | -0.74 | -0.59 | -0.81 | -0.89 | -0.79 |
| Surprise | 0 | -0.25 | 0.0021 | -0.0621 | -0.09 | 0.07 | 0.08 | -0.01 | 0.35 | 0.04 | 0.01 | -0.05 |
| Surprise Percentage | 0% | -34.2466% | 0.2436% | -7.4114% | -12.8571% | 10% | 10.8108% | -1.3514% | 59.322% | 4.9383% | 1.1236% | -6.3291% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-27 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.53 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: FDMT
2026-02-23 12:20:53
4D Molecular Therapeutics is preparing for its quarterly financial results and crucial Phase 3 data release in 2026. Investors are closely watching the company's financial runway and the progress of its wet AMD gene therapy trial. The upcoming quarterly report on February 27, 2026, will shed light on clinical trial timelines and cash burn rates, while topline data from the Phase 3 "4FRONT" study for wet age-related macular degeneration is expected in the first and second halves of the year.
2026-02-19 12:57:54
4D Molecular Therapeutics (FDMT) announced that its management will participate in three healthcare investor conferences in March 2026. The company will present and hold one-on-one meetings at events hosted by TD Cowen, Leerink, and Barclays, with webcasts of the presentations available for up to one year on its investor relations site. This news comes as the company continues to advance its late-stage biotechnology therapeutics, including 4D-150 for retinal vascular diseases and 4D-710 for cystic fibrosis.
2026-02-19 08:00:00
4D Molecular Therapeutics, Inc. (Nasdaq: FDMT) announced that its management will present and hold one-on-one meetings at several upcoming investor conferences in March 2026, including the TD Cowen 46th Annual Health Care Conference, Leerink Global Healthcare Conference, and Barclays 28th Annual Global Healthcare Conference. The company is a late-stage biotechnology firm focused on developing durable, disease-targeted therapeutics, with lead product candidates 4D-150 for retinal vascular diseases and 4D-710 for cystic fibrosis.
2026-02-19 03:00:17
4D Molecular Therapeutics (4DMT) announced its participation in several investor conferences in March, including the TD Cowen 46th Annual Health Care Conference, Leerink Global Healthcare Conference, and Barclays 28th Annual Global Healthcare Conference. Management will present and engage in one-on-one meetings to discuss the company's progress in advancing late-stage gene therapies for blinding retinal vascular diseases and cystic fibrosis. The company is focused on its lead product candidates, 4D-150 and 4D-710, which aim to transform treatment paradigms for these conditions.
2026-02-14 01:27:19
4D Molecular Therapeutics (4DMT) announced that on February 10, 2026, its compensation committee granted 124,200 Restricted Stock Units (RSUs) to nine new non-executive employees. These grants were made under the company’s 2025 Employment Inducement Award Plan, in accordance with Nasdaq rules, to incentivize new hires. 4DMT is a late-stage biotechnology company focused on developing gene therapies for diseases like wet age-related macular degeneration and cystic fibrosis.
2026-02-13 21:05:00
4D Molecular Therapeutics, Inc. (Nasdaq: FDMT) announced that on February 10, 2026, its compensation committee granted 124,200 Restricted Stock Units (RSUs) to nine new non-executive employees. These grants were made under the Company's 2025 Employment Inducement Award Plan to attract new talent. 4DMT is a late-stage biotechnology company focused on developing therapies for diseases like wet age-related macular degeneration and cystic fibrosis.
